Literature DB >> 23233446

A proteomics and transcriptomics approach to identify leukemic stem cell (LSC) markers.

Francesco Bonardi1, Fabrizia Fusetti, Patrick Deelen, Djoke van Gosliga, Edo Vellenga, Jan Jacob Schuringa.   

Abstract

Interactions between hematopoietic stem cells and their niche are mediated by proteins within the plasma membrane (PM) and changes in these interactions might alter hematopoietic stem cell fate and ultimately result in acute myeloid leukemia (AML). Here, using nano-LC/MS/MS, we set out to analyze the PM profile of two leukemia patient samples. We identified 867 and 610 unique CD34(+) PM (-associated) proteins in these AML samples respectively, including previously described proteins such as CD47, CD44, CD135, CD96, and ITGA5, but also novel ones like CD82, CD97, CD99, PTH2R, ESAM, MET, and ITGA6. Further validation by flow cytometry and functional studies indicated that long-term self-renewing leukemic stem cells reside within the CD34(+)/ITGA6(+) fraction, at least in a subset of AML cases. Furthermore, we combined proteomics with transcriptomics approaches using a large panel of AML CD34(+) (n = 60) and normal bone marrow CD34(+) (n = 40) samples. Thus, we identified eight subgroups of AML patients based on their specific PM expression profile. GSEA analysis revealed that these eight subgroups are enriched for specific cellular processes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23233446      PMCID: PMC3591656          DOI: 10.1074/mcp.M112.021931

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  58 in total

Review 1.  Biology of hematopoietic stem cells and progenitors: implications for clinical application.

Authors:  Motonari Kondo; Amy J Wagers; Markus G Manz; Susan S Prohaska; David C Scherer; Georg F Beilhack; Judith A Shizuru; Irving L Weissman
Journal:  Annu Rev Immunol       Date:  2002-12-17       Impact factor: 28.527

Review 2.  Proteomics: the first decade and beyond.

Authors:  Scott D Patterson; Ruedi H Aebersold
Journal:  Nat Genet       Date:  2003-03       Impact factor: 38.330

3.  The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells.

Authors:  C T Jordan; D Upchurch; S J Szilvassy; M L Guzman; D S Howard; A L Pettigrew; T Meyerrose; R Rossi; B Grimes; D A Rizzieri; S M Luger; G L Phillips
Journal:  Leukemia       Date:  2000-10       Impact factor: 11.528

Review 4.  Mass spectrometry-based proteomics.

Authors:  Ruedi Aebersold; Matthias Mann
Journal:  Nature       Date:  2003-03-13       Impact factor: 49.962

5.  Large-scale analysis of the yeast proteome by multidimensional protein identification technology.

Authors:  M P Washburn; D Wolters; J R Yates
Journal:  Nat Biotechnol       Date:  2001-03       Impact factor: 54.908

6.  Negative regulation of platelet clearance and of the macrophage phagocytic response by the transmembrane glycoprotein SHPS-1.

Authors:  Takuji Yamao; Tetsuya Noguchi; Osamu Takeuchi; Uichi Nishiyama; Haruhiko Morita; Tetsuya Hagiwara; Hironori Akahori; Takashi Kato; Kenjiro Inagaki; Hideki Okazawa; Yoshitake Hayashi; Takashi Matozaki; Kiyoshi Takeda; Shizuo Akira; Masato Kasuga
Journal:  J Biol Chem       Date:  2002-08-07       Impact factor: 5.157

7.  Prognostically useful gene-expression profiles in acute myeloid leukemia.

Authors:  Peter J M Valk; Roel G W Verhaak; M Antoinette Beijen; Claudia A J Erpelinck; Sahar Barjesteh van Waalwijk van Doorn-Khosrovani; Judith M Boer; H Berna Beverloo; Michael J Moorhouse; Peter J van der Spek; Bob Löwenberg; Ruud Delwel
Journal:  N Engl J Med       Date:  2004-04-15       Impact factor: 91.245

8.  Identification of a gene expression signature associated with pediatric AML prognosis.

Authors:  Tomohito Yagi; Akira Morimoto; Mariko Eguchi; Shigeyoshi Hibi; Masahiro Sako; Eiichi Ishii; Shuki Mizutani; Shinsaku Imashuku; Misao Ohki; Hitoshi Ichikawa
Journal:  Blood       Date:  2003-05-08       Impact factor: 22.113

9.  Osteoblastic cells regulate the haematopoietic stem cell niche.

Authors:  L M Calvi; G B Adams; K W Weibrecht; J M Weber; D P Olson; M C Knight; R P Martin; E Schipani; P Divieti; F R Bringhurst; L A Milner; H M Kronenberg; D T Scadden
Journal:  Nature       Date:  2003-10-23       Impact factor: 49.962

10.  Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia.

Authors:  Kazutaka Ozeki; Hitoshi Kiyoi; Yuka Hirose; Masanori Iwai; Manabu Ninomiya; Yoshihisa Kodera; Shuichi Miyawaki; Kazutaka Kuriyama; Chihiro Shimazaki; Hideki Akiyama; Miki Nishimura; Toshiko Motoji; Katsuji Shinagawa; Akihiro Takeshita; Ryuzo Ueda; Ryuzo Ohno; Nobuhiko Emi; Tomoki Naoe
Journal:  Blood       Date:  2003-11-06       Impact factor: 22.113

View more
  35 in total

1.  An Integrated Platform for Isolation, Processing, and Mass Spectrometry-based Proteomic Profiling of Rare Cells in Whole Blood.

Authors:  Siyang Li; Brian D Plouffe; Arseniy M Belov; Somak Ray; Xianzhe Wang; Shashi K Murthy; Barry L Karger; Alexander R Ivanov
Journal:  Mol Cell Proteomics       Date:  2015-03-09       Impact factor: 5.911

Review 2.  Biology and relevance of human acute myeloid leukemia stem cells.

Authors:  Daniel Thomas; Ravindra Majeti
Journal:  Blood       Date:  2017-02-03       Impact factor: 22.113

3.  An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.

Authors:  L Angenendt; S Reuter; D Kentrup; A S Benk; F Neumann; J Hüve; A C Martens; C Schwöppe; T Kessler; L H Schmidt; T Sauer; C Brand; J-H Mikesch; G Lenz; R M Mesters; C Müller-Tidow; W Hartmann; E Wardelmann; D Neri; W E Berdel; C Roesli; C Schliemann
Journal:  Leukemia       Date:  2017-06-30       Impact factor: 11.528

Review 4.  Divergent modulation of normal and neoplastic stem cells by thrombospondin-1 and CD47 signaling.

Authors:  Sukhbir Kaur; David D Roberts
Journal:  Int J Biochem Cell Biol       Date:  2016-05-06       Impact factor: 5.085

5.  A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis.

Authors:  Xiaoyan Xu; Yumeng Wang; Kamalika Mojumdar; Zhicheng Zhou; Kang Jin Jeong; Lingegowda S Mangala; Shuangxing Yu; Yiu Huen Tsang; Cristian Rodriguez-Aguayo; Yiling Lu; Gabriel Lopez-Berestein; Anil K Sood; Gordon B Mills; Han Liang
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

Review 6.  Adhesion GPCRs in Tumorigenesis.

Authors:  Gabriela Aust; Dan Zhu; Erwin G Van Meir; Lei Xu
Journal:  Handb Exp Pharmacol       Date:  2016

7.  Improved surfaceome coverage with a label-free nonaffinity-purified workflow.

Authors:  Tina Glisovic-Aplenc; Saar Gill; Lynn A Spruce; Ian R Smith; Hossein Fazelinia; Olga Shestova; Hua Ding; Sarah K Tasian; Richard Aplenc; Steven H Seeholzer
Journal:  Proteomics       Date:  2017-03-06       Impact factor: 3.984

8.  RUNX1 mutations enhance self-renewal and block granulocytic differentiation in human in vitro models and primary AMLs.

Authors:  Mylène Gerritsen; Guoqiang Yi; Esther Tijchon; Jorren Kuster; Jan Jacob Schuringa; Joost H A Martens; Edo Vellenga
Journal:  Blood Adv       Date:  2019-02-12

9.  Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.

Authors:  Harald Herrmann; Irina Sadovnik; Gregor Eisenwort; Thomas Rülicke; Katharina Blatt; Susanne Herndlhofer; Michael Willmann; Gabriele Stefanzl; Sigrid Baumgartner; Georg Greiner; Axel Schulenburg; Niklas Mueller; Werner Rabitsch; Martin Bilban; Gregor Hoermann; Berthold Streubel; Daniel A Vallera; Wolfgang R Sperr; Peter Valent
Journal:  Blood Adv       Date:  2020-10-27

10.  Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up.

Authors:  Thomas Boyer; Fanny Gonzales; Adriana Plesa; Pauline Peyrouze; Adeline Barthelemy; Soizic Guihard; Bruno Quesnel; Christophe Roumier; Claude Preudhomme; Meyling Cheok
Journal:  J Vis Exp       Date:  2018-03-26       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.